Several therapies from a range of drug classes are available to address the symptoms of narcolepsy; these symptoms include excessive daytime sleepiness (EDS) and cataplexy. Despite the availability of these treatments, a large proportion of patients have inadequate control of their narcolepsy symptoms, leaving opportunity for new agents to address these shortcomings. Given that narcolepsy treatment is highly individualized and complex, understanding the use of current therapies in the nuanced narcolepsy treatment algorithm ahead of anticipated product launches is essential. Our Treatment Algorithms research leverages national patient-level claims data to explore the uptake and use of key therapies for narcolepsy, such as modafinil, armodafinil, psychostimulants, antidepressants, and agents approved to treat EDS or EDS and cataplexy symptoms in narcolepsy, such as Harmony Biosciences’ Wakix, and Jazz Pharmaceuticals’ Xyrem, Xywav, and Sunosi in both newly diagnosed and recently treated patients.
Geographies: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Armodafinil, modafinil, Sunosi, Vyvanse, Xyrem, Xywav, Wakix
Key companies covered: Eli Lilly, Harmony Biosciences, Jazz Pharmaceuticals, Takeda, Teva
Key analysis provided:
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.